The scientist’s investigation covers issues in Positron emission tomography, Nuclear medicine, Radiology, Internal medicine and Cancer. His work carried out in the field of Positron emission tomography brings together such families of science as Clinical trial, Cervix, Rectum, Esophageal cancer and Recurrent Colorectal Carcinoma. Barry A. Siegel combines subjects such as Cervical cancer, Carcinoma, Radiation therapy and Lymph node with his study of Nuclear medicine.
His studies deal with areas such as Prospective cohort study, Lung cancer, Metastasis and Adenocarcinoma as well as Radiology. The concepts of his Internal medicine study are interwoven with issues in Standardized uptake value and Oncology. As a member of one scientific family, he mostly works in the field of Cancer, focusing on Gastroenterology and, on occasion, Adverse effect.
Barry A. Siegel mainly investigates Radiology, Nuclear medicine, Positron emission tomography, Internal medicine and Oncology. His work in the fields of Radiology, such as PET-CT, intersects with other areas such as In patient. His Nuclear medicine research includes themes of Magnetic resonance imaging, Prospective cohort study, Lung cancer and Radiation therapy.
His research integrates issues of Colorectal cancer, Carcinoma and Primary tumor, Metastasis in his study of Positron emission tomography. In his research, Platelet is intimately related to Pathology, which falls under the overarching field of Internal medicine. His work deals with themes such as Stage, Lymph node and Cervix, which intersect with Cervical cancer.
Barry A. Siegel focuses on Radiology, Positron emission tomography, PET-CT, Prostate cancer and Internal medicine. His Radiology research is multidisciplinary, relying on both Cervical cancer, Cancer, Lung cancer and Disease. His Positron emission tomography study is focused on Nuclear medicine in general.
His Nuclear medicine study combines topics from a wide range of disciplines, such as Clinical trial, Cohort and Primary tumor. The study incorporates disciplines such as Prostate and Radiation therapy in addition to Prostate cancer. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Oncology.
Barry A. Siegel spends much of his time researching Internal medicine, Nuclear medicine, Oncology, Radiology and PET-CT. His biological study spans a wide range of topics, including Gastroenterology and Standardized uptake value. His Nuclear medicine research incorporates elements of Prostatectomy, Clinical trial, Lymphadenectomy, Lymph node and Multicenter trial.
The various areas that Barry A. Siegel examines in his Radiology study include Cancer, Prostate cancer and Lung cancer. PET-CT is a primary field of his research addressed under Positron emission tomography. Positron emission tomography is frequently linked to Pathology in his study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
Malik E. Juweid;Sigrid Stroobants;Otto S. Hoekstra;Felix M. Mottaghy.
Journal of Clinical Oncology (2007)
Recommendations on the Use of 18F-FDG PET in Oncology
James W. Fletcher;James W. Fletcher;Benjamin Djulbegovic;Heloisa P. Soares;Barry A. Siegel.
The Journal of Nuclear Medicine (2008)
Procedure Guideline for Tumor Imaging with 18F-FDG PET/CT 1.0
Dominique Delbeke;R. Edward Coleman;Milton J. Guiberteau;Manuel L. Brown.
The Journal of Nuclear Medicine (2006)
Consensus Recommendations for the Use of 18F-FDG PET as an Indicator of Therapeutic Response in Patients in National Cancer Institute Trials
Lalitha K. Shankar;John M. Hoffman;Steve Bacharach;Michael M. Graham.
The Journal of Nuclear Medicine (2006)
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Gary J. Kelloff;John M. Hoffman;Bruce Johnson;Howard I. Scher.
Clinical Cancer Research (2005)
Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
Jeffrey Bradley;Wade L. Thorstad;Sasa Mutic;Tom R. Miller.
International Journal of Radiation Oncology Biology Physics (2004)
Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).
Felix G. Fernandez;Jeffrey A. Drebin;David C. Linehan;Farrokh Dehdashti.
Annals of Surgery (2004)
Lymph Node Staging by Positron Emission Tomography in Patients With Carcinoma of the Cervix
Perry W. Grigsby;Barry A. Siegel;Farrokh Dehdashti.
Journal of Clinical Oncology (2001)
Breast cancer: PET imaging of estrogen receptors.
M A Mintun;M J Welch;B A Siegel;C J Mathias.
Impact of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography (PET) Alone on Expected Management of Patients With Cancer: Initial Results From the National Oncologic PET Registry
Bruce E. Hillner;Barry A. Siegel;Dawei Liu;Anthony F. Shields.
Journal of Clinical Oncology (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: